Latest News and Press Releases

- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...

Highlights progress, recent developments and upcoming key milestonesCompany continues to build growing body of data across pipeline, advancing towards first in human studiesStrong financial position...

Live moderated video webcast on Thursday, July 13th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the...

– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and...

Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...

– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET TORONTO, ONTARIO, April 12, 2022 ...

– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund operations beyond 2023 TORONTO,...

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a...

– Company continues to advance clinical and preclinical programs with its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need – Strong...

– Company executing on growth strategy to build-out pipeline of development assets – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021 ...